CN115974802A - Preparation method of bisoprolol fumarate intermediate - Google Patents
Preparation method of bisoprolol fumarate intermediate Download PDFInfo
- Publication number
- CN115974802A CN115974802A CN202211272521.3A CN202211272521A CN115974802A CN 115974802 A CN115974802 A CN 115974802A CN 202211272521 A CN202211272521 A CN 202211272521A CN 115974802 A CN115974802 A CN 115974802A
- Authority
- CN
- China
- Prior art keywords
- bisoprolol fumarate
- fumarate intermediate
- preparing
- compound
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 title claims abstract description 29
- 229960005400 bisoprolol fumarate Drugs 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 19
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003054 catalyst Substances 0.000 claims abstract description 12
- 239000003446 ligand Substances 0.000 claims abstract description 12
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims abstract description 11
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims abstract description 11
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003513 alkali Substances 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052802 copper Inorganic materials 0.000 claims abstract description 4
- 239000010949 copper Substances 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 14
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 9
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims description 8
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- MRVDGKFQFYHDHX-UHFFFAOYSA-N 3-propan-2-yl-5-[[4-(2-propan-2-yloxyethoxymethyl)phenoxy]methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(COCCOC(C)C)=CC=C1OCC1OC(=O)N(C(C)C)C1 MRVDGKFQFYHDHX-UHFFFAOYSA-N 0.000 claims description 3
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 claims description 3
- 229940076286 cupric acetate Drugs 0.000 claims description 2
- 229960004643 cupric oxide Drugs 0.000 claims description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 27
- 230000008569 process Effects 0.000 abstract description 6
- 239000012535 impurity Substances 0.000 abstract description 5
- 238000009776 industrial production Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 13
- 239000000543 intermediate Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- SDGVUJAKIMHHAF-UHFFFAOYSA-N 1-bromo-4-(2-propan-2-yloxyethoxymethyl)benzene Chemical compound CC(C)OCCOCC1=CC=C(Br)C=C1 SDGVUJAKIMHHAF-UHFFFAOYSA-N 0.000 description 6
- RXRVCSDDGFQDOJ-UHFFFAOYSA-N 5-(hydroxymethyl)-3-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)N1CC(CO)OC1=O RXRVCSDDGFQDOJ-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 description 1
- HCGFUIQPSOCUHI-UHFFFAOYSA-N 2-propan-2-yloxyethanol Chemical compound CC(C)OCCO HCGFUIQPSOCUHI-UHFFFAOYSA-N 0.000 description 1
- ISQLWWCGQXEAJG-UHFFFAOYSA-N 4-(2-propan-2-yloxyethoxymethyl)phenol Chemical compound CC(C)OCCOCC1=CC=C(O)C=C1 ISQLWWCGQXEAJG-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to the technical field of drug synthesis, in particular to a preparation method of a bisoprolol fumarate intermediate, which comprises the following steps:
Description
Technical Field
The invention relates to the technical field of drug synthesis, in particular to a preparation method of a bisoprolol fumarate intermediate.
Background
Bisoprolol fumarate is suitable for treating hypertension, coronary heart disease, moderate to severe chronic stable heart failure and other symptoms, has long action time, can realize once-a-day administration, and basically has no adverse effect on lung function. Bisoprolol fumarate was patented in Belgium in 1978, in the United states in 1979 and 1981, respectively, and formally marketed in 4 months 1986, and is currently marketed in more than twenty countries and regions, english, fair, japan, etc. Specific results are as follows.
The main process route of bisoprolol fumarate at present is as follows:
in related patents, 4-hydroxybenzaldehyde is used as a starting material, 4-hydroxybenzyl alcohol is reduced by borohydride, or 4-hydroxybenzyl alcohol is directly used as a raw material to be subjected to etherification reaction with isopropoxy ethanol to obtain 4-isopropoxy ethoxy methyl phenol, epoxy chloropropane is used for substitution to obtain epoxide, isopropylamine is used for epoxy opening to obtain free alkali of bisoprolol, and finally, the fumaric acid is used for salifying to obtain the bisoprolol fumarate.
The above route has the main problem that multiple steps are not provided with oil, which increases the difficulty of purification and causes certain risks for the subsequent API quality. Further, based on patent reports, it is found that after the compound III is constructed, corresponding intermediates are all solids, and can be recrystallized and purified, so that the industrial productivity is greatly improved, and the quality control of API is facilitated, and a corresponding route is as follows.
In further research, we found that the process control difficulty of step 1 is high, and the process impurity compound 07 can be brought into bisoprolol fumarate API to cause API quality risk, thereby causing API quality problem. The process impurity structure is as follows:
since compound 07 cannot be removed below the required limit by conventional purification means and its presence itself has a great risk impact on API quality. Therefore, there is a need to further develop a new synthesis method of compound IV to solve the problems in the bisoprolol fumarate process.
Disclosure of Invention
The purpose of the invention is: overcomes the defects in the prior art, and provides a preparation method of bisoprolol fumarate intermediate with high reaction condition temperature and yield. .
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a method for preparing a bisoprolol fumarate intermediate, said intermediate being 5- ((4- ((2-isopropoxyethoxy) methyl) phenoxy) methyl) -3-isopropyloxazolidin-2-one, comprising the steps of:
heating the compound II and the compound III in an organic solvent to 80-120 ℃ in the presence of alkali, a copper catalyst and a ligand to prepare the key compound IV.
Furthermore, the catalyst can be selected from cuprous bromide, cupric acetate, cuprous iodide and cupric oxide.
Further, cuprous iodide is selected as the catalyst.
Further, the molar ratio of the catalyst to the compound II is 1.
Further, the preferred ratio is 1.
Further, the alkali is cesium carbonate, potassium tert-butoxide or lithium tert-butoxide.
Further, the alkali is potassium tert-butoxide.
Further, the ligand is dibenzoyl tartaric acid (DMTA).
Further, the molar ratio of the ligand to the catalyst is 1:1.
Further, the solvent is one of N, N-dimethylformamide, tetrahydrofuran or dimethyl sulfoxide.
The technical scheme adopted by the invention has the following beneficial effects:
the problems of stability and impurities can be better solved through Ullman reaction, and meanwhile, the inventor unexpectedly finds that the yield can be improved from about 60 percent to more than 80 percent by adding the ligand dibenzoyltartaric acid (DMTA) in the experimental process, and simultaneously, the reaction temperature is further reduced from 140 ℃ to about 80 ℃, so that the method is more favorable for industrial production.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
The preparation method of the bisoprolol fumarate intermediate is 5- ((4- ((2-isopropoxyethoxy) methyl) phenoxy) methyl) -3-isopropyloxazolidin-2-one, and comprises the following steps:
heating the compound II and the compound III in an organic solvent to 80-120 ℃ in the presence of alkali, a copper catalyst and a ligand to prepare the key compound IV.
The problems of stability and impurities can be better solved through Ullman reaction, and meanwhile, the fact that the yield can be improved to more than 80% from about 60% by adding the ligand dibenzoyltartaric acid (DMTA) is unexpectedly found, the reaction temperature is further reduced to about 80 ℃ from 140 ℃, and the method is more favorable for industrial production. From the view of reaction mechanism, it should be because the ligand thereof coordinates with copper ion to lower the activation energy of the reaction and stabilize the intermediate state of the reaction, thereby achieving better results.
Example 1:
in a 2L three-necked reaction flask, a system of 1-bromo-4- ((2-isopropoxyethoxy) methyl) benzene (compound II,50g,1.0 eq), 5- (hydroxymethyl) -3-isopropyloxazolidin-2-one (compound III,32.03 g,1.1 eq) and DMF (350 mL) was added in this order, stirred at room temperature and replaced with nitrogen three times, followed by addition of cuprous iodide (3.5 g,0.1 eq), dibenzoyltartaric acid (DMTA) (6.6 g,0.1 eq) and potassium tert-butoxide (24.6 g,1.2 eq), heating of the system to 80 ℃ for 16 hours, TLC showed complete conversion of the starting material, cooling of the system to room temperature, followed by addition of water (400 mL) to quench the reaction, filtration of the precipitated solid, collection of the filter cake, and vacuum drying to give compound IV (52.7 g yield: 82% off-white solid).
1H-NMR(300MHz,d6-DMSO)δ7.27(d,2H),6.94(d,2H),4.81-4.83(m.1H), 4.43(s,2H),4.18-4.11(m,2H),3.95-3.91(m,1H),3.56-3.39(m,4H),3.37-3.35(m,2H),2.56(s,1H),1.16-1.08(m,12H)。
LCMS(ESI)m/z,352.44(M+H)+
Example 2:
1-bromo-4- ((2-isopropoxyethoxy) methyl) benzene (compound II,50g,1.0 equivalent), 5- (hydroxymethyl) -3-isopropyloxazolidin-2-one (compound III,32.03 g,1.1 equivalent) and DMSO (500 mL) system were added sequentially in a 2L three-port reaction flask, stirred at room temperature and replaced with nitrogen three times, followed by addition of cuprous iodide (7.0 g,0.2 equivalent) and potassium tert-butoxide (24.6 g,1.2 equivalent), the system was heated to 140 ℃ for 18 hours, after TLC showed complete conversion of the starting material, the system was cooled to room temperature, followed by addition of water (800 mL) for quenching reaction, filtration to precipitate a solid, and after collection of the filter cake, silica gel (100-200 mesh) column chromatography to obtain compound IV (37.2 g yield: 58% white-like solid).
Example 3:
1-bromo-4- ((2-isopropoxyethoxy) methyl) benzene (compound II,5g,1.0 equivalent), 5- (hydroxymethyl) -3-isopropyloxazolidin-2-one (compound III, 3.0g,1.1 equivalent) and N-methylpyrrolidone (50 mL) are added in a 100mL three-port reaction flask in sequence, the mixture is stirred at room temperature and replaced by nitrogen for three times, cuprous bromide (0.26g, 0.1 equivalent) and potassium tert-butoxide (2.5g, 1.2 equivalents) are added, the system is heated to 100 ℃ and reacted for 18 hours, TLC shows that the raw materials are completely converted, the system is cooled to room temperature, then water (50 mL) is added to quench the reaction, the solid is separated out by filtration, and after collecting the filter cake, silica gel (100-200 mesh) column chromatography is carried out to obtain compound IV (4.5 g yield: 70% white-like solid).
Example 4:
1-bromo-4- ((2-isopropoxyethoxy) methyl) benzene (compound II,5g,1.0 eq), 5- (hydroxymethyl) -3-isopropyloxazolidin-2-one (compound III, 3.2g,1.1 eq) and DMF (40 mL) were added sequentially to a 100mL three-neck reaction flask, stirred at room temperature and replaced with nitrogen three times, followed by addition of cuprous iodide (0.18g, 0.05 eq), dibenzoyltartaric acid (DMTA) (0.33g, 0.05 eq) and potassium tert-butoxide (2.5g, 1.2 eq), heating the system to 80 ℃ for 16 hours, TLC showed no further conversion of the starting material, cooling the system to room temperature, quenching the reaction in water (400 mL), filtering to precipitate a solid, collecting the filter cake, and purifying by column chromatography (100-200 mesh) to obtain compound IV (3.6 g: 56% white-like solid).
Example 5:
1-bromo-4- ((2-isopropoxyethoxy) methyl) benzene (compound II,5g,1.0 eq), 5- (hydroxymethyl) -3-isopropyloxazolidin-2-one (compound III, 3.2g,1.1 eq) and DMF (50 mL) were added sequentially to a 100mL three-necked reaction flask, the system was stirred at room temperature and replaced with nitrogen three times, then copper acetate (0.33g, 0.1 eq), dibenzoyltartaric acid (DMTA) (0.66g, 0.1 eq) and potassium tert-butoxide (2.5g, 1.2 eq) were added, the system was heated to 80 ℃ for 16 hours, TLC showed complete conversion of the starting material, the system was cooled to room temperature, then water (40 mL) was added to quench the reaction, the solid was precipitated by filtration, the filter cake was collected and purified using (100-200 mesh) to give compound IV (4.5 g yield: 70% white-like solid).
Example 6:
in a 100mL three-necked reaction flask, a system of 1-bromo-4- ((2-isopropoxyethoxy) methyl) benzene (compound II,5g,1.0 equivalent), 5- (hydroxymethyl) -3-isopropyloxazolidin-2-one (compound III, 3.2g,1.1 equivalent) and DMF (50 mL) was added in this order, stirred at room temperature and replaced with nitrogen three times, followed by addition of cuprous iodide (0.35g, 0.1 equivalent), dibenzoyltartaric acid (DMTA) (0.66g, 0.1 equivalent) and cesium carbonate (7.14g, 1.2 equivalent), heating of the system to 80 ℃ for 36 hours, TLC showed complete conversion of the raw material, cooling of the system to room temperature, followed by addition of water (100 mL) to quench the reaction, filtration of the precipitated solid, collection of the filter cake, and purification using (100-200 mesh) to obtain compound IV (4.3 g yield: 66.9% white-like solid).
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present invention should be subject to the appended claims.
Claims (10)
1. A method for preparing a bisoprolol fumarate intermediate, said intermediate being 5- ((4- ((2-isopropoxyethoxy) methyl) phenoxy) methyl) -3-isopropyloxazolidin-2-one, characterized by: the preparation method comprises the following steps:
heating the compound II and the compound III in an organic solvent to 80-120 ℃ in the presence of alkali, a copper catalyst and a ligand to prepare the key compound IV.
2. The method for preparing the bisoprolol fumarate intermediate according to claim 1, characterized in that: the catalyst can be selected from cuprous bromide, cupric acetate, cuprous iodide and cupric oxide.
3. The method for preparing the bisoprolol fumarate intermediate according to claim 2, wherein the bisoprolol fumarate intermediate comprises the following steps: the catalyst is cuprous iodide.
4. The method for preparing the bisoprolol fumarate intermediate according to claim 2, characterized in that: the molar ratio of the catalyst to the compound II is 1.
5. The method for preparing the bisoprolol fumarate intermediate according to claim 4, wherein the bisoprolol fumarate intermediate is prepared from the following raw materials: the preferred ratio is 1.
6. The method for preparing the bisoprolol fumarate intermediate according to claim 1, wherein the bisoprolol fumarate intermediate comprises the following steps: the alkali is cesium carbonate, potassium tert-butoxide or lithium tert-butoxide.
7. The method for preparing the bisoprolol fumarate intermediate according to claim 1, wherein the bisoprolol fumarate intermediate comprises the following steps: the alkali is potassium tert-butoxide.
8. The method for preparing the bisoprolol fumarate intermediate according to claim 1, wherein the bisoprolol fumarate intermediate comprises the following steps: the ligand is dibenzoyltartaric acid (DMTA).
9. The method for preparing the bisoprolol fumarate intermediate according to claim 8, wherein the bisoprolol fumarate intermediate is prepared from the following raw materials: the molar ratio of the ligand to the catalyst was 1:1.
10. The method for preparing the bisoprolol fumarate intermediate according to claim 1, characterized in that: the solvent is one of N, N-dimethylformamide, tetrahydrofuran or dimethyl sulfoxide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211272521.3A CN115974802A (en) | 2022-10-18 | 2022-10-18 | Preparation method of bisoprolol fumarate intermediate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211272521.3A CN115974802A (en) | 2022-10-18 | 2022-10-18 | Preparation method of bisoprolol fumarate intermediate |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115974802A true CN115974802A (en) | 2023-04-18 |
Family
ID=85968789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211272521.3A Pending CN115974802A (en) | 2022-10-18 | 2022-10-18 | Preparation method of bisoprolol fumarate intermediate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115974802A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103664657A (en) * | 2013-11-25 | 2014-03-26 | 四川大学 | New preparation method for bisoprolol fumarate |
CN112194587A (en) * | 2020-11-18 | 2021-01-08 | 江苏悦兴医药技术有限公司 | Preparation method of chiral bisoprolol fumarate |
-
2022
- 2022-10-18 CN CN202211272521.3A patent/CN115974802A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103664657A (en) * | 2013-11-25 | 2014-03-26 | 四川大学 | New preparation method for bisoprolol fumarate |
CN112194587A (en) * | 2020-11-18 | 2021-01-08 | 江苏悦兴医药技术有限公司 | Preparation method of chiral bisoprolol fumarate |
Non-Patent Citations (2)
Title |
---|
HYE SUN LIM ET AL: "Synthesis of Dibenzoxepine Lactams via a Cu-Catalyzed One-Pot Etherification/Aldol Condensation Cascade Reaction: Application toward the Total Synthesis of Aristoyagonine", ORGANIC LETTERS, vol. 15, no. 18, pages 4718 - 4721, XP055814556, DOI: 10.1021/ol402036t * |
HYUNG YOON ET AL: "Atroposelective Desymmetrization of Resorcinol-Bearing Quinazolinones via Cu-Catalyzed C−O Bond Formation", ORGANIC LETTERS, vol. 24, pages 762 - 766 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106905305B (en) | Preparation method of engelizin | |
CN107098822B (en) | Preparation method for pranlukast key intermediate 3-amino-2-hydroxyacetophenone | |
CN110803987A (en) | Preparation method of R- (+) -2- (4-hydroxyphenoxy) propionic acid | |
CN103664657A (en) | New preparation method for bisoprolol fumarate | |
CN110183445A (en) | The synthetic method of Moxifloxacin and its derivative | |
CN115974802A (en) | Preparation method of bisoprolol fumarate intermediate | |
CN110734368B (en) | Preparation method of buparvaquone | |
CN107880004B (en) | Preparation method of 5-phenoxyphthalide | |
CN114716331A (en) | Preparation method of dopamine hydrochloride | |
CN111100042B (en) | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | |
CN111217690B (en) | Preparation method of propafenone hydrochloride and intermediate 2' -hydroxy dihydrochalcone thereof | |
CN105439837B (en) | Synthetic method of 6-bromoisovanillin | |
CN109232544B (en) | Preparation method of prucalopride | |
CN112250586A (en) | Preparation method of terbutaline sulfate and B crystal form thereof | |
CN100357245C (en) | Prepn process of 2,5-dihalogeno benzoic acid | |
JP2021195344A (en) | Method for producing 5-bromo-2-halogenated benzoic acid | |
CA2660358A1 (en) | Process for the preparation of trifluoroethoxytoluenes | |
EP1799632A2 (en) | Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide | |
CN112209841B (en) | Synthesis method of terbutaline and application of terbutaline in preparation of terbutaline sulfate | |
CN111100062A (en) | Synthesis method of donepezil hydrochloride | |
CN116283798B (en) | Novel preparation method of urapidil | |
CN115536558B (en) | Refining process of bumetanide crude product | |
CN111217709A (en) | Preparation method of (1-fluorocyclopropyl) methylamine hydrochloride | |
CN108752339B (en) | A kind of synthetic method of quindoline and its derivative | |
CN111978188B (en) | Preparation method of mexiletine hydrochloride impurity C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |